Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Target Corporation (TGT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Target CorporationTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Target Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Target Corporation trades at $138.64 (market cap $63.40B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Target Corporation pays a 3.32% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

TGTXBI
Market Cap
$63.40B
Sector
Consumer CyclicalBroad Market / Factor
52-Week High
$141.19$164.28
52-Week Low
$83.68$85.16
Enterprise Value
$78.70B
Dividend Yield
3.32%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Target Corporation

With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.

Read more on TGT

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI